Interleukin-6 potentiates endurance training adaptation and improves functional capacity in old mice.
Ageing
Exercise
Fatigue
Frailty
Interleukin-6
Muscle
Myokine
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
18
01
2022
received:
15
11
2021
accepted:
23
01
2022
pubmed:
23
2
2022
medline:
6
4
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Interventions to preserve functional capacities at advanced age are becoming increasingly important. So far, exercise provides the only means to counteract age-related decrements in physical performance and muscle function. Unfortunately, the effectiveness of exercise interventions in elderly populations is hampered by reduced acceptance and compliance as well as disuse complications. We therefore studied whether application of interleukin-6 (IL-6), a pleiotropic myokine that is induced by skeletal muscle activity and exerts broad systemic effects in response to exercise, affects physical performance and muscle function alone or in combination with training in aged mice. Sedentary old male mice (Sed+Saline, n = 15) were compared with animals that received recombinant IL-6 (rIL-6) in an exercise-mimicking pulsatile manner (Sed+IL-6, n = 16), were trained with a moderate-intensity, low-volume endurance exercise regimen (Ex+Saline, n = 13), or were exposed to a combination of these two interventions (Ex+IL-6, n = 16) for 12 weeks. Before and at the end of the intervention, mice underwent a battery of tests to quantify endurance performance, muscle contractility in situ, motor coordination, and gait and metabolic parameters. Mice exposed to enhanced levels of IL-6 during endurance exercise bouts showed superior improvements in endurance performance (33% more work and 12% greater peak power compared with baseline), fatigue resistance in situ (P = 0.0014 vs. Sed+Saline; P = 0.0199 vs. Sed+IL-6; and P = 0.0342 vs. Ex+Saline), motor coordination (rotarod performance, P = 0.0428), and gait (gait speed, P = 0.0053) following training. Pulsatile rIL-6 treatment in sedentary mice had only marginal effects on glucose tolerance and some gait parameters. No increase in adverse events or mortality related to rIL-6 treatment was observed. Administration of rIL-6 paired with treadmill running bouts potentiates the adaptive response to a moderate-intensity low-volume endurance exercise regimen in old mice, while being safe and well tolerated.
Sections du résumé
BACKGROUND
Interventions to preserve functional capacities at advanced age are becoming increasingly important. So far, exercise provides the only means to counteract age-related decrements in physical performance and muscle function. Unfortunately, the effectiveness of exercise interventions in elderly populations is hampered by reduced acceptance and compliance as well as disuse complications. We therefore studied whether application of interleukin-6 (IL-6), a pleiotropic myokine that is induced by skeletal muscle activity and exerts broad systemic effects in response to exercise, affects physical performance and muscle function alone or in combination with training in aged mice.
METHODS
Sedentary old male mice (Sed+Saline, n = 15) were compared with animals that received recombinant IL-6 (rIL-6) in an exercise-mimicking pulsatile manner (Sed+IL-6, n = 16), were trained with a moderate-intensity, low-volume endurance exercise regimen (Ex+Saline, n = 13), or were exposed to a combination of these two interventions (Ex+IL-6, n = 16) for 12 weeks. Before and at the end of the intervention, mice underwent a battery of tests to quantify endurance performance, muscle contractility in situ, motor coordination, and gait and metabolic parameters.
RESULTS
Mice exposed to enhanced levels of IL-6 during endurance exercise bouts showed superior improvements in endurance performance (33% more work and 12% greater peak power compared with baseline), fatigue resistance in situ (P = 0.0014 vs. Sed+Saline; P = 0.0199 vs. Sed+IL-6; and P = 0.0342 vs. Ex+Saline), motor coordination (rotarod performance, P = 0.0428), and gait (gait speed, P = 0.0053) following training. Pulsatile rIL-6 treatment in sedentary mice had only marginal effects on glucose tolerance and some gait parameters. No increase in adverse events or mortality related to rIL-6 treatment was observed.
CONCLUSIONS
Administration of rIL-6 paired with treadmill running bouts potentiates the adaptive response to a moderate-intensity low-volume endurance exercise regimen in old mice, while being safe and well tolerated.
Identifiants
pubmed: 35191221
doi: 10.1002/jcsm.12949
pmc: PMC8978011
doi:
Substances chimiques
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1176Subventions
Organisme : Universität Basel
Organisme : SystemsX.ch
Organisme : Swiss Society for Research on Muscle Diseases
Organisme : Krebsforschung Schweiz
ID : KFS-3733-08-2015
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Organisme : Innosuisse - Schweizerische Agentur für Innovationsförderung
ID : 44112.1 IP-LS
Organisme : European Research Council
ID : 616830-MUSCLE_NET
Pays : International
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Adv Enzyme Regul. 2002;42:249-59
pubmed: 12123719
JCI Insight. 2020 Oct 15;5(20):
pubmed: 32941181
Science. 2020 May 1;368(6490):
pubmed: 32355002
Med Sci Sports Exerc. 2000 Jan;32(1):70-84
pubmed: 10647532
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Clin Interv Aging. 2020 Sep 16;15:1675-1690
pubmed: 32982201
Nat Med. 2011 Oct 30;17(11):1481-9
pubmed: 22037645
Physiol Rev. 2008 Oct;88(4):1379-406
pubmed: 18923185
JAMA. 2011 Jan 5;305(1):50-8
pubmed: 21205966
Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H829-34
pubmed: 10710351
J Clin Endocrinol Metab. 2003 Jul;88(7):3005-10
pubmed: 12843134
Diabetes. 2004 Jul;53(7):1643-8
pubmed: 15220185
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Pharmacol Res. 2020 Apr;154:104191
pubmed: 30844535
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Rejuvenation Res. 2015 Feb;18(1):57-89
pubmed: 25431878
Exp Neurol. 2007 Sep;207(1):23-9
pubmed: 17560573
Front Physiol. 2021 Aug 12;12:709807
pubmed: 34456749
Neuropathology. 2006 Feb;26(1):32-42
pubmed: 16521477
Gerontology. 2017;63(1):91-100
pubmed: 27760421
Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E155-62
pubmed: 15383370
J Physiol. 2009 Jan 15;587(1):211-7
pubmed: 19001042
BMC Geriatr. 2011 Aug 18;11:47
pubmed: 21851629
Physiology (Bethesda). 2017 Mar;32(2):152-161
pubmed: 28228482
Calcif Tissue Int. 2019 Feb;104(2):137-144
pubmed: 30244338
J Clin Invest. 2020 Jun 1;130(6):2888-2902
pubmed: 32078586
Cancer Chemother Pharmacol. 2008 Nov;62(6):995-1007
pubmed: 18270703
Sports Med. 2018 Feb;48(2):467-479
pubmed: 28623613
Mol Syst Biol. 2020 Apr;16(4):e9247
pubmed: 32323921
Med Sci Sports Exerc. 2011 Jul;43(7):1177-87
pubmed: 21131862
J Appl Physiol (1985). 2005 Apr;98(4):1154-62
pubmed: 15772055
Endocrinology. 2009 Apr;150(4):1850-60
pubmed: 19022895
Lancet. 2005 May 21-27;365(9473):1817-20
pubmed: 15910955
Front Physiol. 2019 Jan 14;9:1915
pubmed: 30692935
Science. 2014 Oct 31;346(6209):587-91
pubmed: 25359967
Pflugers Arch. 2014 Aug;466(8):1647-57
pubmed: 24221357
J Physiol. 1996 Dec 1;497 ( Pt 2):573-80
pubmed: 8961197
J Physiol. 2018 Jul;596(14):2883-2900
pubmed: 29726007
PLoS One. 2016 Jun 21;11(6):e0156460
pubmed: 27327080
FEBS J. 2013 Sep;280(17):4131-48
pubmed: 23663276
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1164-1176
pubmed: 35191221
Cell Metab. 2019 Apr 2;29(4):844-855.e3
pubmed: 30595477
Scand J Med Sci Sports. 2015 Dec;25 Suppl 3:1-72
pubmed: 26606383